NL-OMON50977
Completed
Not Applicable
A preoperative program to promote peri- and postoperative health in patients undergoing thoracic aortic surgery: a randomized controlled trial. - MAS study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- thoracic aortic disease
- Sponsor
- Radboud Universitair Medisch Centrum
- Enrollment
- 3
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
Trial ended prematurely
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients that are:
- •\- visiting the cardiothoracic surgery outpatient clinic prior to probable
- •thoracic aortic surgery;
- •\- aged 18 years or older;
- •\- able to understand and perform study related procedures.
Exclusion Criteria
- •Patients that are:
- •\- unable to provide signed and dated informed consent form;
- •\- wheelchair\-bounded or physically unable to stand or walk;
- •\- currently enrolled in another interventional study targeting either sedentary
- •behaviour and/or physical activity.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Verification of preoperative screening for bleeding tendency in patients that report bleeding symptomshemorrhagic diathesisbleeding tendency100644771000533010047075NL-OMON40106niversiteit Maastricht439
Completed
Not Applicable
A prospective, multicenter clinical study to evaluate the safety profile of the FlexiSurge Adhesion Barrier for the prevention of intra-abdominal adhesion formation after laparotomyvorming van adhesies na buikchirurgieadhesion formationpostoperative adhesionsNL-OMON40303Medisse BV5
Completed
Not Applicable
A prospective clinical follow up study with a New Press-fit Cup with initial RSA analysis (NPC).Osteoarthritisworn hip10023213NL-OMON46964Stichting SCORE28
Completed
Phase 2
A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab in combination with other anti-cancer therapies in participants with lymphomanon-Hodgkin Peripheral T-cell lymfomenHodgkin and non-Hodgkin lymphomaleukemia1002531910025320NL-OMON48105Sanofi-aventis7
Completed
Not Applicable
A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Myeloid Malignanciesbeenmergstoornis: MDS (myelodysplastisch syndroom/myelodysplasie)Acute myeloid leukemiacancer of the bloodmyelodysplastic Syndrome10024324NL-OMON55859Amgen10